Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor...
$XBI, which is a biotech ETF, is showing a potential bearish 2-1-2 continuation on the quarterly chart. Because of this, I will be looking at biotech stocks for a short.
SPDR S&P Biotech ETF ( AMEX:XBI ) Sector: Miscellaneous (Investment Trusts/Mutual Funds) Market Capitalization: $ -- Current Price: $81.20 Breakout price: $84.40 Buy Zone (Top/Bottom Range): $80.50-$74.75 Price Target: $99.10-$100.80 Estimated Duration to Target: 75-81d Contract of Interest: $XBI 12/16/22 85c Trade price as of publish date: $5.40/contract
All description on the chart. Please, don't forget to like and follow. Thank you.
NASDAQ:NERV NERV is already well into the breakout (100%) with a massive volume surge. Probably too late to get into a buy high entry. I will watch this for the fade from the parabolic move to take a short or put option. NASDAQ:NERV
NASDAQ:MNMD Yj This stock had a quick response to good earnings and it is now at resistance with the RSI swing indicator printing a Sell Signal. The MACD, a lagging indicator, shows the signal above the histogram without a K / D cross not yet started. I would like to take a short trade setting a stop loss above the resistance zone and targeting 10% to the POC...
LABU a 3x leveraged EFT in the biotechnology sector has diverse holdings. My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market. Here I chart LABU / QQQ ratio to determine relative strength. On this weekly chart, the ratio and so relative strength are at more than a 52 week low. The MACD indicator shows the...
NASDAQ:LXRX LXRX has gained over 100% in the past month However it appears to be forming a double top in a potential short trade setup on the two hour chart. The K/D crossover on the hot RSI oscillator provides confirmation. Short Sale Volume is rising in the past two days. Findamentals - LXRX has a new medication for heart failure a common medical problem...
NYSE:NVTA a NASDAQ Penny Stock moving 10% today after an earnings loss with a pullback and rebound. Speculative but possibly with a good risk to reward since it has already pulled back. Stochastic RSI is low and all of this follows a long period of consolidation. RElative up volume today is 10-15X baseline showing good accumulation. Options for January 23...
NASDAQ:UBX and rises over 100 % in premarket, Has a new product for macular degeneration, a widespread medical problem affecting vision in the elderly which is increasing in incidence. The earning beat was significant. Chart demonstrates the uptrend and midrange RSI but does not show today's premarket. 40 % rise in the week leading up to earnings and now...
Looking at the NVTA Invitae Corporation options chain, i would buy the $2.5 strike price calls with 2023-1-20 expiration date for about $0.60 premium. Looking forward to read your opinion about it.
Biotech has been hammered since Feb 2021. This ETF is still down 50% + from it's all time high. It formed a double bottom and now a small bullish flag. Target is 97. Longer term 122,134
Moderna, Inc. ( NASDAQ:MRNA ) Sector: Health Technology (Biotechnology) Market Capitalization: $74.178B Current Price: $186.49 Breakout Price: $189.50 Buy Zone (Top/Bottom Range): $180.95-$147.05 Price Target: $204.50-$208.80 (1st), $258.80-$263.70 (2nd) Estimated Duration to Target: 34-37d, 91-96d Contract of Interest: $MRNA 9/16/22 190c, $MRNA 10/21/22...
by @newsfile on 2 Aug 2022, 03:15 Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development...
All description on the chart. Please, don't forget to like and follow. Thank you.
All description on the chart. Please, don't forget to like and follow. Thank you.
^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in...
Beautiful capitulation wick, two strong trendline confluence, TD 13 I'm LOVING this chart.